{
    "clinical_study": {
        "@rank": "89098", 
        "arm_group": {
            "arm_group_label": "Ulthera\u00ae System Treatment", 
            "arm_group_type": "Experimental", 
            "description": "Ulthera\u00ae System treatment of the peri-orbital and peri-oral regions."
        }, 
        "brief_summary": {
            "textblock": "This is prospective, multi-center, single-blinded, non-randomized clinical trial. Enrolled\n      subjects will receive two Ulthera\u00ae treatments on the peri-orbital and peri-oral regions,\n      each treatment provided 30 days apart. Follow-up visits will occur at 90 and 180 days\n      following treatment. Study images will be obtained pre-treatment, immediately\n      post-treatment, and at each follow-up visit."
        }, 
        "brief_title": "Peri-orbital and Peri-oral Wrinkle Reduction Trial", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Peri-orbital Wrinkles", 
            "Peri-oral Wrinkles"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female, age 30 to 75 years.\n\n          -  Subject in good health.\n\n          -  BMI<25\n\n          -  Fitzpatrick wrinkle score of 3-7 in the peri-orbital and peri-oral areas.\n\n          -  Moderate skin laxity in the peri-orbital area contributing to rhytids as assessed by\n             the investigator.\n\n          -  Understands and accepts the obligation not to undergo any other procedures, including\n             neurotoxin and filler treatments, on the face through the follow-up period.\n\n          -  Willingness to refrain from use of aspirin, Ibuprofen, Naproxen or any other NSAID,\n             and Vitamin E in the 2 weeks prior to each study treatment.\n\n          -  Willingness and ability to continue with their current daily skin care routine, with\n             the exception of any use of products containing glycolic acid, for the duration of\n             the study.\n\n          -  Willingness and ability to comply with protocol requirements, including returning for\n             follow-up visits and abstaining from exclusionary procedures for the duration of the\n             study.\n\n          -  Subjects of childbearing potential must have a negative urine pregnancy test result\n             and must not be lactating at the Screening Visit and be willing and able to use an\n             acceptable method of birth control during the study.\n\n          -  Absence of physical or psychological conditions unacceptable to the investigator.\n\n          -  Willingness and ability to provide written consent for study-required photography and\n             adherence to photography procedures (i.e., removal of jewelry and makeup).\n\n          -  Willingness and ability to provide written informed consent and HIPAA authorization\n             prior to performance of any study-related procedure.\n\n        Exclusion Criteria:\n\n          -  Presence of an active systemic or local skin disease that may affect wound healing.\n\n          -  BMI equal to or greater than 25\n\n          -  Severe solar elastosis.\n\n          -  Excessive subcutaneous fat in the area(s) to be treated.\n\n          -  Mild or severe skin laxity on the area(s) to be treated.\n\n          -  Significant scarring in the area(s) to be treated.\n\n          -  Open wounds or lesions in the area(s) to be treated.\n\n          -  Severe or cystic acne on the area(s) to be treated.\n\n          -  Active implantables (e.g., pacemakers or defibrillators) or metallic implants in the\n             treatment area.\n\n          -  Inability to understand the protocol or to give informed consent.\n\n          -  Microdermabrasion, or prescription level glycolic acid treatment to the treatment\n             area(s) within 4 weeks prior to study participation or during the study.\n\n          -  Marked asymmetry, ptosis, excessive dermatochalasis, deep dermal scarring, or thick\n             sebaceous skin in the area(s) to be treated.\n\n          -  History of chronic drug or alcohol abuse.\n\n          -  History of autoimmune disease.\n\n          -  History of Bell's Palsy or epilepsy.\n\n          -  History of diabetes.\n\n          -  Has a known allergy, or a known history of sensitivity, to lidocaine, tetracaine,\n             para-aminobenzoic acid (PABA).\n\n          -  Concomitant therapy that, in the investigator's opinion, would interfere with the\n             evaluation of the safety or efficacy of the study device.\n\n          -  Subjects who anticipate the need for surgery or overnight hospitalization during the\n             study.\n\n          -  Subjects who, in the investigator's opinion, have a history of poor cooperation,\n             noncompliance with medical treatment, or unreliability.\n\n          -  Concurrent enrollment in any study involving the use of investigational devices or\n             drugs.\n\n          -  Current smoker or history of smoking in the last five years.\n\n          -  History of the following cosmetic treatments in the area(s) to be treated:\n\n               1. Skin tightening procedure within the past year;\n\n               2. Injectable fillers of any type within the past 12 or 24 months, depending on\n                  type;\n\n               3. Neurotoxins within the past six months;\n\n               4. Ablative resurfacing laser treatment;\n\n               5. Nonablative, rejuvenative laser or light treatment within the past six months;\n\n               6. Surgical dermabrasion or deep facial peels;\n\n               7. Facelift, blepharoplasty, or browlift within the past 2 years; or\n\n               8. Any history of contour threads.\n\n          -  History of using the following prescription medications:\n\n               1. Accutane or other systemic retinoids within the past six months;\n\n               2. Topical Retinoids within the past four weeks;\n\n               3. Antiplatelet agents/Anticoagulants;\n\n               4. Psychiatric drugs that in the investigators opinion would impair the subject\n                  from understanding the protocol requirements or understanding and signing the\n                  informed consent."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "75 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01981252", 
            "org_study_id": "ULT-137"
        }, 
        "intervention": {
            "arm_group_label": "Ulthera\u00ae System Treatment", 
            "description": "Focused ultrasound energy delivered below the surface of the skin", 
            "intervention_name": "Ulthera\u00ae System Treatment", 
            "intervention_type": "Device", 
            "other_name": "Ultherapy\u00ae"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Ulthera\u00ae System", 
            "Ultherapy\u2122 Treatment", 
            "Ulthera, Inc.", 
            "Micro-focused Ultrasound with Visualization (MFU-V)"
        ], 
        "lastchanged_date": "May 16, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beverly Hills", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90212"
                    }, 
                    "name": "Center for Advanced Facial Plastic Surgery"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Laguna Beach", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92651"
                    }, 
                    "name": "Aesthetic Plastic Surgical Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Englewood", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80113"
                    }, 
                    "name": "About Skin Dermatology and DermSurgery, PC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Coral Gables", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33146"
                    }, 
                    "name": "Dermatology Research Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Nashville Centre for Laser and Facial Surgery"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Evaluation of the Safety and Efficacy of the Ulthera\u00ae System for Wrinkle Reduction in the Peri-orbital and Peri-oral Regions", 
        "overall_official": {
            "affiliation": "Nashville Centre for Laser and Facial Surgery", 
            "last_name": "Brian Biesman, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Assessment of improvement, in a blinded fashion, using the Fitzpatrick Wrinkle Scale at 90 days post-treatment #2.", 
            "measure": "Number of participants with reduction in peri-orbital and/or peri-oral wrinkles at 90 days post-treatment #2.", 
            "safety_issue": "No", 
            "time_frame": "Participants will be followed to 90 days post-treatment #2"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01981252"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Assessment of improvement, in a blinded fashion, using the Fitzpatrick Wrinkle Scale at 180 days post-treatment #2.", 
                "measure": "Number of participants with reduction in peri-orbital and/or peri-oral wrinkles at 180 days Post Treatment #2.", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed to 180 days post-treatment #2"
            }, 
            {
                "description": "Quantitative wrinkle depth measurements will be performed using a 3-D imaging system at 90 days post-treatment #2.", 
                "measure": "Number of participants with a reduction in peri-orbital and/or peri-oral wrinkle depth at 90 days post treatment #2.", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed to 90 days post-treatment #2"
            }, 
            {
                "description": "Quantitative wrinkle depth measurements will be performed using a 3-D imaging system at 180 days post-treatment #2.", 
                "measure": "Number of participants with a reduction in peri-orbital and/or peri-oral wrinkle depth at 180 days Post Treatment #2.", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed to 180 days post-treatment #2"
            }, 
            {
                "description": "Overall aesthetic improvement at 90 days post treatment #2 compared to baseline will be assessed using the Global Aesthetic Improvement Scale (GAIS).", 
                "measure": "Overall Aesthetic Improvement", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed to 90 days post-treatment #2"
            }, 
            {
                "description": "Overall aesthetic improvement at 180 days post treatment #2 compared to baseline will be assessed using the Global Aesthetic Improvement Scale (GAIS).", 
                "measure": "Overall Aesthetic Improvement", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed to 180 days post-treatment #2"
            }, 
            {
                "description": "Subject satisfaction will be measured at using a Patient Satisfaction Questionnaire.", 
                "measure": "Subject Satisfaction", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed to 90 days post-treatment #2"
            }
        ], 
        "source": "Ulthera, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ulthera, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}